Aiforia signs a partnership agreement with Urban Datalab to advance AI-based digital pathology in South Korea
Aiforia Technologies Plc, Press Release, October 8, 2024 at 09:00 a.m. EEST
Aiforia signs a partnership agreement with Urban Datalab to advance AI-based digital pathology in South Korea
Aiforia Technologies, a pioneer in AI-powered pathology image analysis, today announced a partnership with Urban Datalab, a leader in digital healthcare AI in South Korea. This collaboration seeks to accelerate the adoption of Aiforia’s AI solutions in digital pathology across South Korean hospitals. By combining the strengths and collective expertise of Aiforia and Urban Datalab, the companies aim to improve diagnostic accuracy, increase workflow efficiency, and enhance patient care.
“The digital pathology market is expanding rapidly in South Korea, and hospitals are increasingly interested in implementing AI solutions to streamline and enhance pathologists’ workflow. This partnership marks a significant step in making AI more accessible to the South Korean healthcare sector, addressing the growing needs of pathologists and medical professionals. Urban Datalab is an ideal distribution partner for us to enter the South Korean market,” says Jukka Tapaninen, CEO of Aiforia.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com